Skip to main content

Table 1 Patient characteristics

From: Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes

 

Controls

T2DM without LGE

T2DM with ischemic LGEa

T2DM with non-ischemic LGE

P valueb

P valuec

Number

25

207

32

25

Age, years

57 IQR50–64

59 IQR50–67

64 IQR56–69.5

64 IQR57–72

0.008

0.06

Body mass index, kg/m2

25.1 ± 3.3

31.0 ± 4.7

31.9 ± 4.9

30.8 ± 3.7

 < 0.001

0.8

Male sex (n,%)

17 (68)

140 (68)

24 (75)

23 (92)

0.08

Diabetes duration, years

12.2 ± 8.2

12.4 ± 8.0

15.4 ± 9.0

0.20

Systolic blood pressure, mmHg

133 ± 16

134 ± 18

142 ± 21

142 ± 14

0.04

0.06

Diastolic blood pressure, mmHg

81 ± 10

81 ± 9

82 ± 13

81 ± 9

0.98

Active or former smoker (n,%)

11 (44)

135 (65)

29 (91)

16 (64)

0.003

1.0

History of ischemic heart disease (n,%)

15 (7)

26 (81)

3 (12)

 < 0.001

0.4

History of hypertension (n,%)

4 (25)

137 (66)

28 (87.5)

21 (84)

 < 0.001

0.07

NYHA class II/III (n,%)

41 (20)

8 (25)

6 (24)

0.82

Insulin treatment (n,%)

120 (58)

18 (56)

18 (72)

0.38

HbA1c, mmol/mol

35 ± 3

62 ± 15

62 ± 16

64 ± 14

 < 0.001

0.65

Creatinine, µmol/L

86 IQR67–89

71 IQR59–86

75 IQR65–87

74 IQR65–90

0.052

LDL cholesterol, mmol/L

3.0 IQR2.2–3.7

1.9 IQR1.5–2.5

1.4 IQR1.2–2.0

1.8 IQR1.3–2.8

0.0001

0.68

High–sensitive CRP, mg/L

2.1 IQR1.0–4.3

2.3 IQR1.0–4.0

2.5 IQR1.3–5.2

0.57

Pro-BNP, µmol/L

5.9 IQR5.9–10.1

8.0 IQR5.9–17.3

8.9 IQR5.9–19.7a

0.02

0.02

High-sensitive TNT, ng/L

13.0 IQR13.0–14.6

13.6 IQR13.0–17.6

15.6 IQR13.0–26.1a

0.008

0.0007

Pro-ANP, µmol/L

57 IQR42–90

108 IQR47–174

75.5 IQR48–127

0.01

0.1

  1. Data presented as median and interquartile range (IQR) or as nominal values with percentages in parentheses
  2. aIncluding three patients with both ischemic and non-ischemic lesions
  3. bComparison between all three groups as appropriate
  4. cComparison between T2DM patients with non-ischemic LGE vs. T2DM patients without LGE